- Radiopharm Theranostics is boosting its portfolio with the addition of three different nanobodies from NanoMab Technology.
- The Company has acquired full intellectual property (IP) ownership to the assets, targeting TROP-2, HER-2 and PTK7.
- Nano-mAbs technology has high potential in both diagnostic and therapeutic applications.
- Under a licence agreement, the Company has been using NanoMab nanobodies in its Phase 1 clinical and pre-clinical studies.
Driven ahead by its mission to target diagnosis and treatment of a range of solid tumors, Radiopharm Theranostics Limited (ASX:RAD) has hit a significant milestone of acquiring full intellectual property (IP) ownership to three blazing NanoMab assets.
The clinical-stage radiotherapeutics company will acquire the patents to three different nanobodies from NanoMab Technology Ltd, targeting solid tumor pathways, TROP-2 (Triple Negative Breast Cancer and other tumour types), HER-2 (breast cancer), and PTK7 (multiple solid tumours).
For the acquisition of the NanoMab IP, the Company will issue US$500,000 in fully paid RAD ordinary shares.
This development is a great step forward in fulfilling the firm’s objective of developing radiopharmaceuticals products that cater to the unmet medical needs in treating oncological diseases.
The distinct platform tech: Nano-mAbs
An invention of a well-known radiopharmaceutical and nuclear medicine expert Dr. Hong Hoi Ting, Nano-mAbs technology possesses high potential in both diagnostic and therapeutic applications.
Nano-mAbs are made using genetically engineered camelid derived single domain antibodies (sdAb), which can be labelled with radioisotopes for the diagnosis and treatment of several tumour types.
Image source: © Auremar | Megapixl.com
Under a licence agreement, the Company has been using NanoMab nanobodies in its Phase 1 clinical and pre-clinical studies.
The Company has already completed a Phase 1 study with its collaborators at Shanghai General Hospital and NanoMab. The study, investigating the safety, dosimetry and efficacy of the RAD201 asset, targets HER-2 positive breast cancer subjects.
The results so far received have indicated the potential to use NanoMab’s nanobodies for imaging and treatment of HER-2+ cancers with different medical radioisotopes. Meanwhile, final candidate selection for TROP2 and PTK7 is underway.
Comment by Riccardo Canevari, RAD’s Managing Director and Chief Executive Officer
“Acquiring the IP for these assets supports Radiopharm’s strategy to focus on innovation and it will allow us to further accelerate clinical development of these multiple assets. We are excited to build on our existing portfolio of worldwide IP rights with these assets from Nanomab Technology Ltd.”
Stock information: RAD shares were trading at AU$0.320 on the Australian Securities Exchange (ASX) midday on 25 January 2022. The Company has a market capitalisation of AU$88.66 million.